Regeneron protocol R668-BP-1902: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid – CURRENTLY ENROLLING

• A Phase II/III clinical trial for adults with moderate to severe bullous pemphigoid investigating Dupixent.

Dupixent

• Now enrolling a clinical trial for adults (up to age 90) with bullous pemphigoid. Patients will receive dupixent or placebo, along with a standardized dose of oral prednisone. 36 weeks, followed by a 12-week follow-up.